CCM
BIIB icon

CAAS Capital Management’s Biogen BIIB Stock Holding History

CAAS Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,000
Closed -$6M – 672
2021
Q4 		$6M Buy
+25,000
New +$6.43M 0.15% 158
2020
Q3 		– Sell
-4,800
Closed -$1.34M – 483
2020
Q2 		$1.28M Buy
+4,800
New +$1.44M 0.04% 248

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CAAS Capital Management's BIIB Position: Q1 2022 in Review

CAAS Capital Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 25,000 shares — an estimated $6M sold.

CAAS Capital Management first reported a position in BIIB in Q2 2020 and held it in 2 quarters. The position peaked at $6M in Q4 2021. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • CAAS Capital Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Biogen shares in Q1 2022, an estimated $6M.
  • CAAS Capital Management first reported a position in Biogen in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Biogen position peaked at $6M in Q4 2021.
  • 952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.